MET amplification + MET Exon 14 mutation
|
NSCLC
|
MET amplification + MET Exon 14 mutation
|
NSCLC
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
MET amplification + MET Exon 14 mutation
|
LUAD
|
MET amplification + MET Exon 14 mutation
|
LUAD
|
savolitinib Sensitive: C4 – Case Studies
|
savolitinib Sensitive: C4 – Case Studies
|